GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

One of the medicines, naltrexone, has shown a small effect size on alcohol-use disorder, Hendershot told CNN. The semaglutide trial showed effect sizes “in the medium to large range,” he said, ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.